Event-free survival in randomized trials of chemotherapy +/− rituximab.
| Disease . | First Author . | Ref. . | Chemotherapy . | n . | Line of Treatment . | No Rituximab . | + Rituximab . | P-value . |
|---|---|---|---|---|---|---|---|---|
| * Patients underwent a second randomization stratified by age to either HDCT/SCT versus IFN or between two doses of IFN | ||||||||
| ** Patients underwent a second randomization to +/− rituximab maintenance. | ||||||||
| † PFS from time of randomization (add approx 6 m for induction CVP). | ||||||||
| † responding patients received IFN maintenance. | ||||||||
| Abbreviations: DLBCL, diffuse large B cell lymphoma; CVP, cyclophosphamide, vincristine, prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; MCP, mitoxantrone, chlorambucil, predisolone; FCM, fludarabine, cyclophosphamide, mitoxantrone; HDCT, high-dose chemotherapy; SCT, stem cell transplantation; IFN, interferon; PFS, progression-free survival | ||||||||
| Follicular | Marcus | (23) | CVP | 322 | 1st | 7 m | 27 m | 0.0001 |
| Hiddemann | (32) | CHOP* | 557 | 1st | 30 m | Not reached | < 0.0001 | |
| Herold | (33) | MCP† | 201 | 1st | 19 m | Not reached | < 0.0001 | |
| Hagenbeck | (24) | CHOP** | 369 | Relapsed | 20 m | 47 m | 0.03 | |
| Dreyling | (25) | FCM | 67 | Relapsed | 20 m | 51 m | 0.00003 | |
| DLBCL | Feugier | (20) | CHOP | 399 | 1st | 13 m | 45 m | 0.00002 |
| Mantle cell | Lenz* | (31) | CHOP | 122 | 1st | 14 m | 21 m | 0.013 |
| Herold | (33) | MCP | 90 | 1st | 14 m | 20 m | 0.24 | |
| Forstpointner | (27) | FCM | 48 | Relapsed | 4 m | 8 m | 0.4 | |
| Disease . | First Author . | Ref. . | Chemotherapy . | n . | Line of Treatment . | No Rituximab . | + Rituximab . | P-value . |
|---|---|---|---|---|---|---|---|---|
| * Patients underwent a second randomization stratified by age to either HDCT/SCT versus IFN or between two doses of IFN | ||||||||
| ** Patients underwent a second randomization to +/− rituximab maintenance. | ||||||||
| † PFS from time of randomization (add approx 6 m for induction CVP). | ||||||||
| † responding patients received IFN maintenance. | ||||||||
| Abbreviations: DLBCL, diffuse large B cell lymphoma; CVP, cyclophosphamide, vincristine, prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; MCP, mitoxantrone, chlorambucil, predisolone; FCM, fludarabine, cyclophosphamide, mitoxantrone; HDCT, high-dose chemotherapy; SCT, stem cell transplantation; IFN, interferon; PFS, progression-free survival | ||||||||
| Follicular | Marcus | (23) | CVP | 322 | 1st | 7 m | 27 m | 0.0001 |
| Hiddemann | (32) | CHOP* | 557 | 1st | 30 m | Not reached | < 0.0001 | |
| Herold | (33) | MCP† | 201 | 1st | 19 m | Not reached | < 0.0001 | |
| Hagenbeck | (24) | CHOP** | 369 | Relapsed | 20 m | 47 m | 0.03 | |
| Dreyling | (25) | FCM | 67 | Relapsed | 20 m | 51 m | 0.00003 | |
| DLBCL | Feugier | (20) | CHOP | 399 | 1st | 13 m | 45 m | 0.00002 |
| Mantle cell | Lenz* | (31) | CHOP | 122 | 1st | 14 m | 21 m | 0.013 |
| Herold | (33) | MCP | 90 | 1st | 14 m | 20 m | 0.24 | |
| Forstpointner | (27) | FCM | 48 | Relapsed | 4 m | 8 m | 0.4 | |